Clinical Trials Logo

Erosive Esophagitis clinical trials

View clinical trials related to Erosive Esophagitis.

Filter by:

NCT ID: NCT01452776 Completed - Erosive Esophagitis Clinical Trials

Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis

Start date: September 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety of long term use of TAK-438, once daily (QD), for the maintenance treatment of healed erosive esophagitis.

NCT ID: NCT01452698 Completed - Erosive Esophagitis Clinical Trials

Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of TAK-438, once daily (QD), compared to lansoprazole in patients with erosive esophagitis of Grade A to D as defined by the LA classification grading system.

NCT ID: NCT01306799 Completed - Barrett's Esophagus Clinical Trials

To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use

BE-CAST
Start date: January 2010
Phase: N/A
Study type: Observational

Patients with severe acid reflux and/or Barrett's esophagus are recommended to take Proton pump inhibitors (PPIs)indefinitely to prevent complications such as strictures or the development of a type of esophageal cancer. Recently, some studies suggested that taking these medications on a long-term basis may affect the bone. Therefore, it is important to learn whether these medications may lead to accelerated bone loss so that effective preventive measures can be developed for patients who require these medications for acid-related conditions. Several studies reported that patients receiving PPIs for many years may have increased risk of hip fractures. However, it is unclear whether this is because the PPIs cause reduced bone density or whether the increased risk of fractures has nothing to do with PPIs and is because patients who require PPIs have other illnesses that cause the increased fractures. The purpose of the study is to learn how bone structure and bone mass change after long-term PPI use.

NCT ID: NCT00693225 Completed - Erosive Esophagitis Clinical Trials

Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study

Start date: January 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study was to determine the effect of morning versus bedtime administration of omeprazole/sodium bicarbonate (Zegerid) on endoscopic healing for patients with moderate or severe reflux esophagitis. Our hypothesis was that bedtime administration of Zegerid would be superior in healing esophagitis compared to morning administration prior to a meal.

NCT ID: NCT00644735 Completed - Erosive Esophagitis Clinical Trials

Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed

Start date: December 2002
Phase: Phase 4
Study type: Interventional

A study to look at the rates of remission (non re-appearance of erosive esomeprazole) when treated with esomeprazole or lansoprazole; in patients in with erosive esomeprazole (EE) that is in remission (i.e. previously healed EE).

NCT ID: NCT00641602 Completed - Erosive Esophagitis Clinical Trials

A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis

Start date: December 2002
Phase: Phase 4
Study type: Interventional

This study looks at the healing rates in patients with Erosive Esophagitis (EE) when treated with either esomeprazole or lansoprazole

NCT ID: NCT00586963 Completed - GERD Clinical Trials

Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis

EE
Start date: January 2008
Phase: N/A
Study type: Observational

This study is being done to for two reasons: - To learn about the effects (good and bad) esomeprazole (an FDA approved drug for reflux esophagitis) has on your esophagus when taken correctly. - To learn about the quality of life changes (good and bad) you may experience with this medication.

NCT ID: NCT00228527 Completed - Clinical trials for Gastroesophageal Reflux Disease (GERD)

Esomeprazole for Treatment of GERD in Pediatric Patients

Start date: October 2004
Phase: Phase 4
Study type: Interventional

To look at the safety and improvement in symptoms of a once a day dosing of esomeprazole in children 1 to 11 years old with inflammation of their esophagus or food pipe ("esophagitis") caused by gastroesophageal reflux disease (GERD) and diagnosed by endoscopy. To verify the healing of the esophageal inflammation if the endoscopy reveals cuts in the lining of the food pipe. To collect information that will describe the psychological, social, and economic effects on the primary caregiver of raising children ages 1 to 5 years old with GERD.

NCT ID: NCT00206180 Completed - Clinical trials for Gastroesophageal Reflux Disease

NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis

Start date: June 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and 40 mg once daily.